drugset / Trial / NCT01265602

Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis

NCT01265602

Phase 3 Completed 889 enrolled Almirall, S.A.
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this study is to determine the efficacy, safety and tolerability of LAS41007 compared to a marketed reference product as well as to vehicle (topical application, twice daily, indication mild to moderate AK).

Timeline

Start
2010-11
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Diclofenac Other / unclassified 0.5 g Topical
Comparator LASW1510 Unknown 0.5 g Topical

Indications